ストックスクリーナーアプリを入手
6.21
3.16%
0.19
アフターアワーズ：
6.13
-0.08
-1.29%
前日終値:
$6.02
開ける：
$6.05
24時間の取引高:
584.97K
Relative Volume:
0.64
時価総額：
$311.14M
収益：
$124.00K
当期純損益:
$-49.99M
株価収益率:
-3.6746
EPS:
-1.69
ネットキャッシュフロー:
$-31.03M
1週間 パフォーマンス:
-1.58%
1か月 パフォーマンス:
+6.88%
6か月 パフォーマンス:
-25.09%
1年 パフォーマンス:
+8.76%
1日の値動き範囲:
$6.00
$6.3699
1週間の範囲:
$5.74
$6.375
52週間の値動き範囲:
$3.785
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
CADL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
6.21 | 298.61M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-30 | 再開されました | H.C. Wainwright | Buy |
| 2025-02-20 | 開始されました | Citigroup | Buy |
| 2025-02-19 | 開始されました | Canaccord Genuity | Buy |
| 2025-02-07 | 開始されました | BofA Securities | Buy |
| 2022-12-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-08-23 | 開始されました | Credit Suisse | Outperform |
| 2021-08-23 | 開始されました | Jefferies | Buy |
| 2021-08-23 | 開始されました | UBS | Buy |
すべてを表示
Candel Therapeutics Inc (CADL) 最新ニュース
Candel Therapeutics CADL 2025Q2 Earnings Preview Downside Ahead on Lack of Revenue Data - AInvest
Cancer Vaccines Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon - The Globe and Mail
Candel Therapeutics Institutional Ownership Soars to 44%: Implications for Stock Price Sensitivity - AInvest
How strong is Candel Therapeutics Inc. company’s balance sheetAchieve explosive financial results today - Jammu Links News
What are the latest earnings results for Candel Therapeutics Inc.Achieve consistent double-digit growth - Jammu Links News
What are Candel Therapeutics Inc. company’s key revenue driversCapitalize on market trends early - Jammu Links News
Is it the right time to buy Candel Therapeutics Inc. stockMaximize profits with strategic stock selection - Jammu Links News
How many analysts rate Candel Therapeutics Inc. as a “Buy”Dynamic investment growth - Jammu Links News
What catalysts could drive Candel Therapeutics Inc. stock higher in 2025Phenomenal returns - Jammu Links News
Candel Therapeutics Inc. Stock Analysis and ForecastUnlock powerful portfolio management tools - Jammu Links News
Is Candel Therapeutics Inc. stock overvalued or undervaluedFree Technical Analysis Support - Jammu Links News
What makes Candel Therapeutics Inc. stock price move sharplyGain the edge with real-time market data - Jammu Links News
Is Candel Therapeutics Inc. a growth stock or a value stockFree Stock Data Feed Backed By Experts - jammulinksnews.com
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - MSN
Applying Wyckoff theory to Candel Therapeutics Inc. stockTop Gaining Picks With Entry Signals Identified - metal.it
Candel Therapeutics CMO Garrett Buys, Sells Shares Amid Company's Market Performance. - AInvest
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Why Candel Therapeutics Inc. stock attracts strong analyst attentionMomentum Based Equity Trading Plans Reviewed - beatles.ru
Candel Therapeutics to share company update at Canaccord Genuity Growth Conference - Proactive financial news
Candel Therapeutics CEO Dr. Tak to Share Cancer Immunotherapy Progress at Major Growth Conference - Stock Titan
Is Candel Therapeutics Inc. Stock a Good Fit for Conservative InvestorsAI Driven Buy Alert Trade Blueprint Released - metal.it
Published on: 2025-07-29 16:45:46 - metal.it
What machine learning models say about Candel Therapeutics Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
Options Data Show Bullish Bias in Candel Therapeutics Inc.High Conviction Intraday Stock Signals Detected - beatles.ru
How does Candel Therapeutics Inc. generate profit in a changing economyNavigate market shifts with confidence - jammulinksnews.com
What is Candel Therapeutics Inc. company’s growth strategyExceptional market positioning - Jammu Links News
Will Candel Therapeutics Inc. Stock Benefit from AI and Green Energy TrendsTechnical Breakout List - metal.it
What is the dividend policy of Candel Therapeutics Inc. stockAchieve consistent profits with proven methods - Jammu Links News
What are the technical indicators suggesting about Candel Therapeutics Inc.Massive profits - jammulinksnews.com
What drives Candel Therapeutics Inc. stock priceFree Real-Time Stock Data - PrintWeekIndia
What analysts say about Candel Therapeutics Inc. stockMarket-leading profit generation - Autocar Professional
Is Candel Therapeutics Inc. a good long term investmentExplosive returns - PrintWeekIndia
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer - GlobeNewswire
Candel Therapeutics' CAN-2409 Receives European Orphan Designation for Pancreatic Cancer Treatment - citybuzz -
Can Candel Therapeutics Inc. stock recover from recent declineExceptional return forecasts - jammulinksnews.com
Small cap wrap: Blockmate Ventures, Candel Therapeutics, HIVE Digital, American Resources... - Proactive financial news
Candel Therapeutics Gets European Orphan Status for Pancreatic Cancer Drug CAN-2409 - citybiz
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409 - Proactive financial news
Revolutionary Pancreatic Cancer Treatment Shows 31.4-Month Survival, Secures Critical EU Designation - Stock Titan
Candel Therapeutics: Promising Phase 3 Data and Secured Financial Runway Justifies Buy Rating - AInvest
Candel Therapeutics Inc (CADL) 財務データ
収益
当期純利益
現金流量
EPS
1.02%
3.70%
大文字化:
|
ボリューム (24 時間):